Clinical Trials Browser

Hormone Sensitive Prostate Cancer × Nivolumab × 90 days × Clear all

NCT04126070 2026-05-27

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Phase 2 Active not recruiting

47 enrolled 16 charts

Hormone Sensitive Prostate Cancer